$7 M

KOOL Mkt cap, 30-Nov-2018

$2 M

Cesca Therapeutics Revenue Q2, 2018
Cesca Therapeutics Gross profit (Q2, 2018)363 K
Cesca Therapeutics Gross profit margin (Q2, 2018), %18.1%
Cesca Therapeutics Net income (Q2, 2018)-27.2 M
Cesca Therapeutics EBIT (Q2, 2018)-30.5 M
Cesca Therapeutics Cash, 30-Jun-20183.1 M

Cesca Therapeutics Revenue

Cesca Therapeutics revenue was $14.53 m in FY, 2017

Embed Graph

Cesca Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.0m16.0m11.9m14.5m

Revenue growth, %

0%(26%)

Cost of goods sold

10.1m11.3m9.2m8.7m

Gross profit

5.9m4.7m2.7m5.8m

Gross profit Margin, %

37%30%23%40%

Sales and marketing expense

3.0m3.0m2.1m1.5m

R&D expense

3.5m5.9m3.2m2.5m

General and administrative expense

8.5m10.7m8.2m11.1m

Operating expense total

14.9m19.6m13.6m15.1m

EBIT

(9.0m)(14.9m)(10.9m)(9.2m)

EBIT margin, %

(57%)(93%)(91%)(64%)

Interest expense

1.9m10.7m

Interest income

6.0k

Income tax expense

673.0k

Net Income

(8.6m)(14.9m)(18.6m)(29.1m)

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018

Revenue

4.0m3.7m4.6m4.0m2.8m3.3m2.8m3.8m4.0m3.3m3.1m1.9m2.0m

Cost of goods sold

2.5m2.5m3.1m2.9m2.5m2.3m2.4m2.4m2.5m1.9m9.9m1.5m1.6m

Gross profit

1.5m1.2m1.5m1.1m367.0k1.0m408.0k1.4m1.6m1.4m(6.8m)352.0k363.0k

Gross profit Margin, %

38%32%33%28%13%31%14%37%39%42%(221%)19%18%

Sales and marketing expense

687.0k808.0k720.0k787.0k632.0k527.0k537.0k481.0k294.0k335.0k517.0k325.0k359.0k

R&D expense

768.0k1.5m1.5m1.7m1.1m646.0k708.0k670.0k694.0k567.0k1.1m1.0m908.0k

General and administrative expense

1.9m2.2m3.6m3.5m2.6m1.8m1.9m2.2m4.1m2.6m1.7m2.2m2.4m

Operating expense total

3.4m4.5m5.9m6.0m4.3m3.0m3.1m3.3m5.1m3.5m3.3m3.6m30.9m

Depreciation and amortization

160.0k

EBIT

(1.9m)(3.3m)(4.4m)(4.8m)(3.9m)(2.0m)(2.7m)(1.9m)(3.6m)(2.1m)(2.3m)(3.3m)(30.5m)

EBIT margin, %

(46%)(90%)(94%)(120%)(139%)(60%)(97%)(52%)(89%)(65%)(77%)(174%)(1522%)

Interest expense

10.5m2.0k19.0k198.0k361.0k383.0k

Interest income

9.0k18.0k

Income tax expense

3.5m

Net Income

(1.9m)(3.3m)(4.4m)(4.8m)(3.4m)(624.0k)(10.9m)(22.4m)(3.4m)(2.1m)(2.6m)(3.4m)(27.2m)

Cesca Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.8m3.4m5.8m3.5m

Accounts Receivable

6.2k

Inventories

5.6m4.6m

Current Assets

25.3m13.3m12.8m11.5m

Goodwill

13.3m13.2m13.2m14.0m

Total Assets

62.9m50.8m49.9m51.1m

Accounts Payable

3.6m5.1m2.6m2.1m

Current Liabilities

6.4m7.9m5.5m5.5m

Total Liabilities

15.9m17.6m17.9m

Retained Earnings

(122.8m)(137.7m)(156.3m)(187.6m)

Total Equity

48.7m34.9m32.3m33.2m

Financial Leverage

1.3 x1.5 x1.5 x1.5 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018

Cash

6.6m10.7m8.4m4.8m6.6m2.9m7.2m5.6m4.9m3.8m2.5m2.9m3.1m

Accounts Receivable

258.0k

Inventories

4.8m5.9m5.2m5.0m4.0m4.0m3.5m282.0k

Current Assets

17.1m21.5m18.4m15.7m14.3m10.7m15.1m12.2m10.9m10.6m10.3m10.3m10.4m

Goodwill

18.9m13.3m13.2m13.2m13.2m13.2m13.2m13.2m13.2m13.2m14.0m1.3m

Total Assets

47.2m59.2m56.0m53.4m51.9m48.2m52.4m49.2m47.9m46.8m48.9m50.2m23.2m

Accounts Payable

3.0m3.0m3.2m4.7m5.7m4.4m3.3m1.8m2.1m1.9m2.0m2.4m2.0m

Current Liabilities

5.5m5.7m6.6m8.4m8.9m7.4m5.9m3.9m5.4m4.7m5.0m6.4m5.4m

Total Liabilities

16.0m12.9m18.1m19.1m14.3m

Retained Earnings

(120.0m)(126.1m)(130.5m)(135.3m)(141.1m)(141.7m)(152.6m)(178.7m)(182.1m)(184.2m)(187.7m)(190.7m)(217.3m)

Total Equity

41.2m45.6m41.6m37.0m32.3m32.2m35.8m36.3m33.7m31.8m30.8m31.1m9.0m

Financial Leverage

1.1 x1.3 x1.3 x1.4 x1.6 x1.5 x1.5 x1.4 x1.4 x1.5 x1.6 x1.6 x2.6 x

Cesca Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.6m)(14.9m)(18.6m)(29.1m)

Depreciation and Amortization

993.0k1.4m1.2m830.0k

Accounts Receivable

515.0k(459.0k)2.0m(522.0k)

Inventories

(1.3m)416.0k375.0k615.0k

Accounts Payable

(295.0k)1.4m(2.4m)(1.1m)

Cash From Operating Activities

(7.8m)

Cash From Investing Activities

(51.0k)(587.0k)(710.0k)(375.0k)

Cash From Financing Activities

15.8m(189.0k)12.8m5.4m

Free Cash Flow

(8.2m)

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(3.3m)(4.4m)(4.8m)(3.4m)(4.0m)(10.9m)(22.4m)(3.4m)(2.1m)(3.4m)(30.5m)

Depreciation and Amortization

587.0k659.0k261.0k159.0k333.0k

Accounts Receivable

(724.0k)1.6m162.0k896.0k869.0k

Inventories

(430.0k)5.9m5.2m5.0m4.0m568.0k3.5m258.0k(224.0k)(358.0k)

Accounts Payable

(397.0k)3.0m3.2m4.7m5.7m(626.0k)3.3m(832.0k)2.1m1.9m69.0k(242.0k)

Cash From Operating Activities

(6.1m)(4.5m)(2.0m)(2.1m)(6.1m)

Cash From Investing Activities

25.0k(602.0k)(850.0k)

Cash From Financing Activities

5.7m4.7m1.9m1.7m6.5m

Interest Paid

657.0k

Free Cash Flow

(6.4m)(5.1m)(2.2m)(2.3m)(7.0m)

Cesca Therapeutics Ratios

USDY, 2018

Financial Leverage

2.6 x
Report incorrect company information

Cesca Therapeutics Operating Metrics

FY, 2016

Patents Issued

25
Report incorrect company information

Cesca Therapeutics Employee Rating

2.54 votes
Culture & Values
3.4
Work/Life Balance
3.4
Senior Management
3.4
Salary & Benefits
3.1
Career Opportunities
2.8
Source